FIS

FCPM III Services Portfolio holdings

AUM $763M
1-Year Est. Return 23.18%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+23.18%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$763M
AUM Growth
+$262M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
11
New
Increased
Reduced
Closed

Top Buys

1
+$60.3M
2
+$54.1M
3
+$46.2M
4
CBIO
Crescent Biopharma
CBIO
+$21.4M
5
BCYC
Bicycle Therapeutics
BCYC
+$119K

Top Sells

1
+$29.9M
2
+$11.5M
3
+$491K

Sector Composition

1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.99B
$323M 42.3%
9,198,900
-13,484
DYN icon
2
Dyne Therapeutics
DYN
$3.37B
$107M 14.01%
5,462,846
ENGN icon
3
enGene Therapeutics Inc. Common Stock
ENGN
$541M
$87M 11.4%
9,632,561
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$62.1M 8.14%
1,833,333
+1,489,096
MPLT
5
MapLight Therapeutics
MPLT
$1.28B
$56.7M 7.43%
+3,226,400
VOR icon
6
Vor Biopharma
VOR
$810M
$47.3M 6.2%
3,617,354
+3,237,714
REPL icon
7
Replimune Group
REPL
$179M
$27.3M 3.58%
2,808,368
-1,350,000
BCYC
8
Bicycle Therapeutics
BCYC
$372M
$24.6M 3.22%
3,468,430
+16,100
CBIO
9
Crescent Biopharma
CBIO
$648M
$19.9M 2.61%
+1,677,852
ENGNW icon
10
enGene Therapeutics Inc. Warrants
ENGNW
$25.7M
$8.52M 1.12%
2,878,148
ATXS
11
DELISTED
Astria Therapeutics
ATXS
– –
-4,107,537